The inhibition of HIF-1α has previously been shown to reduce tumor-induced immune suppression (59, 60), and B+A combination therapy has the potential to reprogram the tumor microenvironment and facilitate anti-tumor immune responses. The gene discussed is HIF1A; the disease is neoplasm.